Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 397

1.

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.

Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, Kabbara N, Barkaoui M, Miron J, Chalard F, Milne P, Haroche J, Cohen F, Hélias-Rodzewicz Z, Simon N, Jehanne M, Kolenova A, Pagnier A, Aladjidi N, Schneider P, Plat G, Lutun A, Sonntagbauer A, Lehrnbecher T, Ferster A, Efremova V, Ahlmann M, Blanc L, Nicholson J, Lambilliote A, Boudiaf H, Lissat A, Svojgr K, Bernard F, Elitzur S, Golan M, Evseev D, Maschan M, Idbaih A, Slater O, Minkov M, Taly V, Collin M, Alvarez JC, Emile JF, Héritier S.

J Clin Oncol. 2019 Sep 12:JCO1900456. doi: 10.1200/JCO.19.00456. [Epub ahead of print]

PMID:
31513482
2.

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Costantini A, Takam Kamga P, Dumenil C, Chinet T, Emile JF, Giroux Leprieur E.

Cancers (Basel). 2019 Aug 29;11(9). pii: E1269. doi: 10.3390/cancers11091269. Review.

3.

Response to trametinib of histiocytosis with an activating PTPN11 mutation.

Farnault L, Hélias-Rodzewicz Z, Venton G, Fanciullino R, Gabriel S, Mescam L, Haroche J, Donadieu J, Emile JF.

Leuk Lymphoma. 2019 Aug 8:1-4. doi: 10.1080/10428194.2019.1650175. [Epub ahead of print] No abstract available.

PMID:
31393194
4.

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Landi B, Blay JY, Bonvalot S, Brasseur M, Coindre JM, Emile JF, Hautefeuille V, Honore C, Lartigau E, Mantion G, Pracht M, Le Cesne A, Ducreux M, Bouche O; «Thésaurus National de Cancérologie Digestive (TNCD)» (Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale de Centres de Lutte Contre les Cancers (UNICANCER); Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR); Société Française de Chirurgie Digestive (SFCD); Société Française de Radiothérapie Oncologique (SFRO); Société Française d’Endoscopie Digestive (SFED); Société Nationale Française de Gastroentérologie (SNFGE).

Dig Liver Dis. 2019 Sep;51(9):1223-1231. doi: 10.1016/j.dld.2019.07.006. Epub 2019 Aug 3. Review.

PMID:
31387778
5.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

6.

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab.

Ouaknine Krief J, Helly de Tauriers P, Dumenil C, Neveux N, Dumoulin J, Giraud V, Labrune S, Tisserand J, Julie C, Emile JF, Chinet T, Giroux Leprieur E.

J Immunother Cancer. 2019 Jul 10;7(1):176. doi: 10.1186/s40425-019-0658-1.

7.

Progress towards molecular-based management of childhood Langerhans cell histiocytosis.

Héritier S, Emile JF, Hélias-Rodzewicz Z, Donadieu J.

Arch Pediatr. 2019 Jul;26(5):301-307. doi: 10.1016/j.arcped.2019.05.015. Epub 2019 Jul 4.

PMID:
31281037
8.

Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.

Dacosta-Noble P, Costantini A, Dumenil C, Dumoulin J, Helly de Tauriers P, Giraud V, Labrune S, Emile JF, Alvarez JC, Chinet T, Giroux Leprieur E.

PLoS One. 2019 Jul 1;14(7):e0219080. doi: 10.1371/journal.pone.0219080. eCollection 2019.

9.

Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.

Bonnet P, Chasset F, Moguelet P, Abisror N, Itzykson R, Bouaziz JD, Hirsch P, Barbaud A, Haroche J, Mekinian A, Hélias-Rodzewicz Z, Clappier E, Fenaux P, Fain O, Tazi A, Emile JF; EMSED and MINHEMON.

Haematologica. 2019 Jun 20. pii: haematol.2019.223552. doi: 10.3324/haematol.2019.223552. [Epub ahead of print]

10.

Inherited IL-18BP deficiency in human fulminant viral hepatitis.

Belkaya S, Michailidis E, Korol CB, Kabbani M, Cobat A, Bastard P, Lee YS, Hernandez N, Drutman S, de Jong YP, Vivier E, Bruneau J, Béziat V, Boisson B, Lorenzo-Diaz L, Boucherit S, Sebagh M, Jacquemin E, Emile JF, Abel L, Rice CM, Jouanguy E, Casanova JL.

J Exp Med. 2019 Aug 5;216(8):1777-1790. doi: 10.1084/jem.20190669. Epub 2019 Jun 18.

PMID:
31213488
11.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

Bruzzi M, Auclin E, Lo Dico R, Voron T, Karoui M, Espin E, Cianchi F, Weitz J, Buggenhout A, Malafosse R, Denimal F, Le Malicot K, Vernerey D, Douard R, Emile JF, Lepage C, Laurent-Puig P, Taieb J.

Ann Surg Oncol. 2019 Oct;26(11):3561-3567. doi: 10.1245/s10434-019-07513-6. Epub 2019 Jun 17.

PMID:
31209667
12.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
13.

Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J.

Haematologica. 2019 May 23. pii: haematol.2019.216937. doi: 10.3324/haematol.2019.216937. [Epub ahead of print]

14.

Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Papo M, Cohen-Aubart F, Trefond L, Bauvois A, Amoura Z, Emile JF, Haroche J.

Curr Oncol Rep. 2019 May 21;21(7):62. doi: 10.1007/s11912-019-0810-6. Review.

PMID:
31115724
15.

Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort.

Kambouchner M, Emile JF, Copin MC, Coulomb-Lherminé A, Sabourin JC, Della Valle V, Sileo C, Ducou Le Pointe H, Bégueret H, Galmiche L, Lambilliotte A, Paraf F, Piche M, Piguet C, Rullier A, Secq V, Serre I, Bernaudin JF, Donadieu J.

Hum Pathol. 2019 Jul;89:51-61. doi: 10.1016/j.humpath.2019.04.005. Epub 2019 May 3.

PMID:
31054893
16.

Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients.

Amoura A, Haroche J, Emile JF, Barete S, Helias-Rodzewicz Z, Charlotte F, Maisonobe T, Amoura Z, Cohen Aubart F.

J Eur Acad Dermatol Venereol. 2019 Apr 19. doi: 10.1111/jdv.15636. [Epub ahead of print] No abstract available.

PMID:
31002424
17.

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.

Roeser A, Cohen-Aubart F, Breillat P, Miyara M, Emile JF, Charlotte F, Donadieu J, Amoura Z, Haroche J.

Haematologica. 2019 Mar 28. pii: haematol.2018.214007. doi: 10.3324/haematol.2018.214007. [Epub ahead of print]

18.

Tubercular splenic abscesses: A rare entity sometimes hard to sterilize.

Matt M, Blot C, Thiry T, Antier A, Peschaud F, Roux AL, Emile JF, Davido B.

Int J Infect Dis. 2019 May;82:18-20. doi: 10.1016/j.ijid.2019.02.048. Epub 2019 Mar 5. No abstract available.

19.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, Merabtene F, Dumont S, Sauvanet A, Hammel P, Cros J, André T, Bachet JB, Bardier A, Douard R, Meatchi T, Peschaud F, Emile JF, Cojean-Zelek I, Laurent-Puig P, Taieb J.

Br J Cancer. 2019 Apr;120(7):697-702. doi: 10.1038/s41416-019-0415-8. Epub 2019 Mar 6.

PMID:
30837681
20.

Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma.

Lemdani K, Mignet N, Boudy V, Seguin J, Oujagir E, Bawa O, Peschaud F, Emile JF, Capron C, Malafosse R.

Oncoimmunology. 2019 Jan 10;8(3):1550342. doi: 10.1080/2162402X.2018.1550342. eCollection 2019.

21.

Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23.

Martínez-Barricarte R, Markle JG, Ma CS, Deenick EK, Ramírez-Alejo N, Mele F, Latorre D, Mahdaviani SA, Aytekin C, Mansouri D, Bryant VL, Jabot-Hanin F, Deswarte C, Nieto-Patlán A, Surace L, Kerner G, Itan Y, Jovic S, Avery DT, Wong N, Rao G, Patin E, Okada S, Bigio B, Boisson B, Rapaport F, Seeleuthner Y, Schmidt M, Ikinciogullari A, Dogu F, Tanir G, Tabarsi P, Bloursaz MR, Joseph JK, Heer A, Kong XF, Migaud M, Lazarov T, Geissmann F, Fleckenstein B, Arlehamn CL, Sette A, Puel A, Emile JF, van de Vosse E, Quintana-Murci L, Di Santo JP, Abel L, Boisson-Dupuis S, Bustamante J, Tangye SG, Sallusto F, Casanova JL.

Sci Immunol. 2018 Dec 21;3(30). pii: eaau6759. doi: 10.1126/sciimmunol.aau6759.

22.

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.

Héritier S, Barkaoui MA, Miron J, Thomas C, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Jeziorski E, Plat G, Aladjidi N, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Pagnier A, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Gandemer V, Martin-Duverneuil N, Taly V, Hélias-Rodzewicz Z, Emile JF, Hoang-Xuan K, Idbaih A, Donadieu J.

Br J Haematol. 2018 Nov;183(4):608-617. doi: 10.1111/bjh.15577. Epub 2018 Nov 12.

PMID:
30421536
23.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.

Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

PMID:
30415988
24.

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C.

Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12.

PMID:
30315348
25.

Contribution of genetic amplification by PCR for the diagnosis of Helicobacter pylori infection in patients receiving proton pump inhibitors.

Bazin T, Nchare Mfondi A, Julie C, Émile JF, Raymond J, Lamarque D.

United European Gastroenterol J. 2018 Oct;6(8):1267-1273. doi: 10.1177/2050640618787055. Epub 2018 Jun 27.

26.

A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.

Bunaux K, Sevestre H, Emile JF, Capel C, Chenin L, Peltier J.

Neurochirurgie. 2018 Dec;64(6):439-441. doi: 10.1016/j.neuchi.2018.08.002. Epub 2018 Sep 28.

PMID:
30274919
27.

Highly sensitive methods are required to detect mutations in histiocytoses.

Melloul S, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Fraitag S, Terrones N, Riller Q, Chazal T, Héritier S, Moreau A, Kambouchner M, Copin MC, Donadieu J, Taly V, Amoura Z, Haroche J, Emile JF.

Haematologica. 2019 Mar;104(3):e97-e99. doi: 10.3324/haematol.2018.201194. Epub 2018 Sep 27. No abstract available.

28.

Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation.

Dupeux M, Boccara O, Frassati-Biaggi A, Hélias-Rodzewicz Z, Leclerc-Mercier S, Bodemer C, Molina TJ, Emile JF, Fraitag S.

Am J Dermatopathol. 2019 Jan;41(1):29-36. doi: 10.1097/DAD.0000000000001255. Review.

PMID:
30252693
29.

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.

Costantini A, Julie C, Dumenil C, Hélias-Rodzewicz Z, Tisserand J, Dumoulin J, Giraud V, Labrune S, Chinet T, Emile JF, Giroux Leprieur E.

Oncoimmunology. 2018 Apr 20;7(8):e1452581. doi: 10.1080/2162402X.2018.1452581. eCollection 2018.

30.

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Franconieri F, Deshayes S, de Boysson H, Trad S, Martin Silva N, Terrier B, Bienvenu B, Galateau-Sallé F, Emile JF, Johnson AC, Aouba A.

Oncoimmunology. 2018 Apr 9;7(8):e1450712. doi: 10.1080/2162402X.2018.1450712. eCollection 2018.

31.

CDKN2A Depletion Causes Aneuploidy and Enhances Cell Proliferation in Non-Immortalized Normal Human Cells.

Hélias-Rodzewicz Z, Lourenco N, Bakari M, Capron C, Emile JF.

Cancer Invest. 2018;36(6):338-348. doi: 10.1080/07357907.2018.1491588. Epub 2018 Aug 23.

PMID:
30136875
32.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

33.

Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.

Cohen-Aubart F, Guerin M, Poupel L, Cluzel P, Saint-Charles F, Charlotte F, Arsafi Y, Emile JF, Frisdal E, Le Goff C, Donadieu J, Amoura Z, Lesnik P, Haroche J, Le Goff W.

Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.

PMID:
29930009
34.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

35.

BRAF V600E mutation detected in a case of Rosai-Dorfman disease.

Fatobene G, Haroche J, Hélias-Rodzwicz Z, Charlotte F, Taly V, Ferreira AM, Abdo ANR, Rocha V, Emile JF.

Haematologica. 2018 Aug;103(8):e377-e379. doi: 10.3324/haematol.2018.190934. Epub 2018 May 10. No abstract available.

36.

Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer.

Giroux Leprieur E, Herbretau G, Dumenil C, Julie C, Giraud V, Labrune S, Dumoulin J, Tisserand J, Emile JF, Blons H, Chinet T.

Oncoimmunology. 2018 Jan 29;7(5):e1424675. doi: 10.1080/2162402X.2018.1424675. eCollection 2018.

37.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL.

Blood. 2018 Jun 28;131(26):2877-2890. doi: 10.1182/blood-2018-03-839753. Epub 2018 May 2. Review.

38.

Rotation of a floating hydrophobic disk: influence of line tension.

Emile J, Tabuteau H, Emile O.

Soft Matter. 2018 May 16;14(19):3829-3833. doi: 10.1039/c8sm00309b.

PMID:
29718056
39.

[Rosai-Dorfman disease: Diagnosis and therapeutic challenges].

Cohen Aubart F, Haroche J, Emile JF, Charlotte F, Barete S, Schleinitz N, Donadieu J, Amoura Z.

Rev Med Interne. 2018 Aug;39(8):635-640. doi: 10.1016/j.revmed.2018.02.011. Epub 2018 Mar 1. Review. French.

PMID:
29501513
40.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association.

Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.

41.

Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort.

Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, Cluzel P, Donadieu J, Idbaih A, Barete S, Amoura Z, Haroche J.

Am J Hematol. 2018 May;93(5):E114-E117. doi: 10.1002/ajh.25055. Epub 2018 Feb 10. No abstract available.

42.

Efficacy of infliximab in the treatment of Erdheim-Chester disease.

Cohen-Aubart F, Maksud P, Emile JF, Benameur N, Charlotte F, Cluzel P, Amoura Z, Haroche J.

Ann Rheum Dis. 2018 Sep;77(9):1387-1390. doi: 10.1136/annrheumdis-2017-212678. Epub 2018 Jan 23. No abstract available.

PMID:
29363511
43.

Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.

Wang L, Dumenil C, Julié C, Giraud V, Dumoulin J, Labrune S, Chinet T, Emile JF, He B, Giroux Leprieur E.

Oncotarget. 2017 Nov 23;8(65):109818-109835. doi: 10.18632/oncotarget.22651. eCollection 2017 Dec 12. Review.

44.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2018 Jul 12;4(7):e173695. doi: 10.1001/jamaoncol.2017.3695. Epub 2018 Jul 12.

45.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
46.

Neurodegeneration in histiocytoses might start in utero.

Haroche J, Cohen-Aubart F, Emile JF, Donadieu J, Amoura Z.

Lancet Neurol. 2017 Dec;16(12):953-954. doi: 10.1016/S1474-4422(17)30373-3. Epub 2017 Oct 27. No abstract available.

PMID:
29111143
47.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

PMID:
28701367
48.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

49.

New somatic BRAF splicing mutation in Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Chakraborty R, Sengal AG, Bellanné-Chantelot C, Thomas C, Moreau A, Fraitag S, Allen CE, Donadieu J, Emile JF.

Mol Cancer. 2017 Jul 6;16(1):115. doi: 10.1186/s12943-017-0690-z.

50.

Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF.

BMC Dermatol. 2017 Jul 1;17(1):9. doi: 10.1186/s12895-017-0061-x.

Supplemental Content

Support Center